Outcome of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia

被引:32
|
作者
Fiorella, ML
Ross, D
Henderson, KJ
White, RI
机构
[1] Yale Univ, Sch Med, Dept Surg, Otolaryngol Sect, New Haven, CT 06519 USA
[2] Yale Univ, Sch Med, Dept Surg & Intervent Radiol, Otolaryngol Sect, New Haven, CT 06519 USA
[3] Yale Univ, Sch Med, Dept Diagnost Radiol, Otolaryngol Sect, New Haven, CT 06519 USA
[4] Univ Bari, Dept Otolaryngol, Bari, Italy
来源
LARYNGOSCOPE | 2005年 / 115卷 / 02期
关键词
septal dermoplasty; epistaxis; hereditary hemorrhagic telangiectasia;
D O I
10.1097/01.mlg.0000154754.39797.43
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: Septal dermoplasty has been recommended as the treatment of choice for lifethreatening epistaxis in patients with hereditary hemorrhagic telangiectasia. The purpose of the study was to evaluate the effectiveness and outcomes of septal dermoplasty for management of transfusion-dependent epistaxis. Study Design: Retrospective study. Methods: Between 1994 and 2004, septal dermoplasty was performed on 67 consecutive patients with severe epistaxis attributable to hereditary hemorrhagic telangiectasia. The numbers of units of blood received 1 year before and 1 year after septal dermoplasty were obtained. A subjective appraisal of the results of the surgery as well as second procedures after septal dermoplasty was determined. Patients were screened for pulmonary and cerebral arteriovenous malformations, gastrointestinal tract bleeding, and symptomatic liver disease. Results: Data were obtained in 66 of 67 (98%) patients with a mean age of 61.5 years (mean follow-up, 3.9 y). Accurate transfusion requirements 1 year before and 1 year after septal dermoplasty were available in 32 of 66 (48%) patients. In these 32 patients, the mean units of blood received decreased from 21 units (range, 2-100 units) I year before septal dermoplasty to 1 unit (range, 0-10 units) in the year after septal dermoplasty (P < .001). Improved quality of life was claimed in 57 patients. Second therapies, ranging from cautery to repeat partial septal dermoplasty, were required in 15 patients during follow-up. Among the 67 patients, 31 (46%) had pulmonary arteriovenous malformation, 14 (21%) had gastrointestinal tract bleeding, 7 (10%) had symptomatic liver disease, and 5 (7%) had cerebral arteriovenous malformation. During the follow-up, 14 patients died of other complications of hereditary hemorrhagic telangiectasia (11 patients) and unrelated causes (3 patients). Conclusion: Septal dermoplasty remains an effective way of reducing transfusion requirements in patients with hereditary hemorrhagic telangiectasia and subjectively improves their quality of life. The otolaryngologist caring for patients with hereditary hemorrhagic telangiectasia. should be familiar with other organ involvement by hereditary hemorrhagic telangiectasia. to prevent complications during surgery.
引用
收藏
页码:301 / 305
页数:5
相关论文
共 50 条
  • [41] Predictors of mortality in patients with hereditary hemorrhagic telangiectasia
    Faughnan, M. E.
    Nelson, J.
    Kim, H.
    Pawlikowska, L.
    Marchuk, D. A.
    Lawton, M. T.
    ANGIOGENESIS, 2019, 22 (04) : 604 - 604
  • [42] Predictors of mortality in patients with hereditary hemorrhagic telangiectasia
    K. P. Thompson
    J. Nelson
    H. Kim
    L. Pawlikowska
    D. A. Marchuk
    M. T. Lawton
    Marie E. Faughnan
    Orphanet Journal of Rare Diseases, 16
  • [43] CONTROL OF EPISTAXIS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA
    SIEGEL, MB
    KEANE, WM
    ATKINS, JP
    ROSEN, MR
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1991, 105 (05) : 675 - 679
  • [44] Cancer incidence in patients with hereditary hemorrhagic telangiectasia
    Christine W. Duarte
    Adam W. Black
    F. Lee Lucas
    Calvin P. H. Vary
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 209 - 214
  • [45] Venous thromboembolism in patients with hemorrhagic hereditary telangiectasia
    Riera-Mestre, A.
    Goemez-Del Olmo, V
    Mora Lujan, J. M.
    Sanchez, R.
    Del Toro, J.
    Falga, C.
    Maho, I
    Valero, B.
    Trujillo-Santos, J.
    Monreal, M.
    ANGIOGENESIS, 2018, 21 (01) : 141 - 142
  • [46] Cancer incidence in patients with hereditary hemorrhagic telangiectasia
    Duarte, Christine W.
    Black, Adam W.
    Lucas, F. Lee
    Vary, Calvin P. H.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (02) : 209 - 214
  • [47] Predictors of mortality in patients with hereditary hemorrhagic telangiectasia
    Thompson, K. P.
    Nelson, J.
    Kim, H.
    Pawlikowska, L.
    Marchuk, D. A.
    Lawton, M. T.
    Faughnan, Marie E.
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [48] MicroRNA Dysregulation in Patients with Hereditary Hemorrhagic Telangiectasia
    Cannavicci, Anthony
    CIRCULATION RESEARCH, 2017, 121
  • [49] Vaccination program for patients with hereditary hemorrhagic telangiectasia
    Botella-Cubells, Luisa Maria
    Zarrabeitia-Puente, Roberto
    Rodriguez-Garcia, Juan
    Ojeda-Fernandez, Maria Luisa
    Garcia-Erce, Jose Antonio
    Fernandez-Santos Rafael
    ANGIOGENESIS, 2015, 18 (04) : 548 - 548
  • [50] Infection prevention in patients with hereditary hemorrhagic telangiectasia
    Rodriguez-Garcia, Juan
    Zarrabeitia-Puente, Roberto
    Fernandez-Santos, Rafael
    Antonio Garcia-Erce, Jose
    HAEMATOLOGICA, 2018, 103 (10) : E491 - E492